Frankfurt The success of the Covid-19 vaccine developer Biontech has brought new attention to German biotech companies. However, regardless of the success of Biontech, the industry has again moved more into the focus of venture capitalists, even if financing and production are still more difficult in Germany than in the USA.
The cancer specialist is one of the drug developers who recently completed major financing rounds T-Knife from Berlin and the company Cardior from Hanover, who developed a new therapy for heart failure.
Both companies are among the hopes of the German biotech scene, whom leading venture capitalists in Europe trust to jump into the front row – and also to go public. The Handelsblatt asked the VC companies TVM, MIG, Wellington, Kurma, Forbion, LSP and Andera Partners.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
–
Further
–
–
Read on now
Get access to this and every other article in the
Web and in our app for 6 weeks.
–
Further
–
–
— .
